InteRNA is a Dutch clinical-stage biotech company developing a pipeline of proprietary RNA therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer. Selected through its leading microRNA (miRNA) discovery and functional validation platform and enabled with a 3rd generation drug delivery formulation, these miRNA compounds can mount a coordinated anti-cancer attack by engaging multiple signal transduction targets simultaneously. With this approach, we address the high need for novel therapeutics with improved efficacy and less prone to drug-acquired resistance that will benefit cancer patients.

miRNAs provide a unique simultaneous regulation of multiple mRNA targets and as such
1. block activated cancer signaling pathways, and
2. prevent activation of alternative cancer signaling pathways,

leading to improved long term control of advanced tumors and reduced relapse rates.

miRNAs and cancer


read more

Technology & IP

InteRNA pursued a new approach to identify the best miRNA candidate/miRNA targets for each disease type considered. The developed miRNA discovery and functional validation platform enabled an unbiased screening approach in R&D focusing on the elucidation of the functional roles of individual miRNAs. This approach gave a direct insight in potential function and allowed for combinatorial screens with e.g. chemo, radiation, targeted kinase inhibitors and immunotherapy to address resistance/ resensitization.

read more



read more